Acta Neuropathologica

, Volume 116, Issue 2, pp 205–213 | Cite as

Ultrastructural localization of TDP-43 in filamentous neuronal inclusions in various neurodegenerative diseases

Original Paper

Abstract

Using post-embedding immunogold electron microscopy, TAR DNA-binding protein of 43 kDa (TDP-43) was localized to neuronal cytoplasmic (NCI) and intranuclear (NII) inclusions, as well as unmyelinated neurites, in frontotemporal lobar degeneration with ubiquitinated inclusions (FTLD-U), amyotrophic lateral sclerosis (ALS), Alzheimer’s (AD), Pick’s disease (PiD) and Lewy body disease (LBD). The TDP-43 immunoreactive structures were morphologically heterogeneous. The most common was characterized by bundles of 10–20 nm diameter straight filaments with electron dense granular material within NCI, NII and neurites. This type of pathology was found in FTLD-U, ALS and some cases of AD. Less often, inclusions in neuritic processes of FTLD-U and some cases of AD contained 10-17 nm diameter straight filaments without granular material. A final type of TDP-43 immunoreactivity was labeling of filaments and granular material associated with tau filaments in neurofibrillary tangles of AD and Pick bodies of PiD or α-synuclein filaments in Lewy bodies of LBD. The results suggest that TDP-43 is the primary component of the granulofilamentous inclusions in FTLD-U and ALS. Similar inclusions sometimes accompany filamentous aggregates composed of other abnormal proteins in AD, PiD and LBD.

Keywords

Alzheimer’s disease Amyotrophic lateral sclerosis Frontotemporal lobar degeneration with ubiquitinated inclusions Immunoelectron microscopy Lewy body disease Pick’s disease TAR DNA-binding protein of 43 kDa (TDP-43) 

References

  1. 1.
    Amador-Ortiz C, Lin WL, Ahmed Z, Personett D, Davies P, Duara R et al (2007) TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer’s disease. Ann Neurol 61:435–445. doi:10.1002/ana.21154 PubMedCrossRefGoogle Scholar
  2. 2.
    Arai T, Hasegawa M, Akiyama H, Ikeda K, Nonaka T, Mori H et al (2006) TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun 351:602–611. doi:10.1016/j.bbrc.2006.10.093 PubMedCrossRefGoogle Scholar
  3. 3.
    Cairns NJ, Newmann M, Bigio EH, Holm IE, Troost D, Hatanpaa KJ, Foong C, White ICL, Schneider JA, Kretzschmar HA, Carter D, Taylor-Reinwald L, Paulsmeyer K, Strider J, Gitcho M, Goate AM, Morris JC, Mishra M, Kwong LK, Stieber A, Xu Y, Forman MS, Trojanowski JQ, Lee VM-Y, Mackenzie IRA (2007) TDP-43 in familial and sporadic frontotemporal lobar degeneration with ubiquitin inclusions. Am J Pathol 171:227–240. doi:10.2353/ajpath.2007.070182 PubMedCrossRefGoogle Scholar
  4. 4.
    Dickson DW, Wertkin A, Mattiace LA, Fier E, Kress Y, Davies P et al (1990) Ubiquitin immunoelectron microscopy of dystrophic neurites in cerebellar senile plaques of Alzheimer’s disease. Acta Neuropathol 79:486–493. doi:10.1007/BF00296107 PubMedCrossRefGoogle Scholar
  5. 5.
    Freeman SH, Spires-Jones T, Hyman BT, Growdon JH, Frosch MP (2008) TDP-DNA binding protein 43 in Pick Disease. J Neuropathol Exp Neurol 67:62–67. doi:10.1097/nen.0b013e3181609361 PubMedCrossRefGoogle Scholar
  6. 6.
    Geser F, Winton MJ, Kwong LK, Xu Y, Xie SX, Igaz LM et al (2008) Pathological TDP-43 in parkinsonism-dementia complex and amyotrophic lateral sclerosis of Guam. Acta Neuropathol 115:133–145. doi:10.1007/s00401-007-0257-y PubMedCrossRefGoogle Scholar
  7. 7.
    Gilman CP, Mattson MP (2002) Do apoptotic mechanisms regulate synaptic plasticity and growth-cone motility? Neuromolecular Med 2:197–214. doi:10.1385/NMM:2:2:197 PubMedCrossRefGoogle Scholar
  8. 8.
    Gwinn-Hardy K, Mehta ND, Farrer M, Maraganore D, Muenter M, Yen SH et al (2000) Distinctive neuropathology revealed by alpha-synuclein antibodies in hereditary Parkinsonism and dementia linked to chromosome 4p. Acta Neuropathol 99:663–672. doi:10.1007/s004010051177 PubMedCrossRefGoogle Scholar
  9. 9.
    Hasegawa M, Arai T, Akiyama H, Nonaka T, Mori H, Hashimoto T et al (2007) TDP-43 is deposited in the Guam parkinsonism-dementia complex brains. Brain 130:1386–1394. doi:10.1093/brain/awm065 PubMedCrossRefGoogle Scholar
  10. 10.
    Hasegawa M, Arai T, Nonaka T, Kametani F, Yoshida M, Hashizume Y, et al. (2008) Phosphorylated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Ann Neurol, Epub ahead of print. doi:10.1002/ana.21425
  11. 11.
    Higashi S, Iseki E, Yamamoto R, Minegishi M, Hino H, Fujisawa K et al (2007) Concurrence of TDP-43, tau and α-synuclein pathology in brains of Alzheimer’s disease and dementia with Lewy bodies. Brain Res 1184:284–294. doi:10.1016/j.brainres.2007.09.048 PubMedCrossRefGoogle Scholar
  12. 12.
    Iseki E, Li F, Odawara T, Hino H, Suzuki K, Kosaka K et al (1998) Ubiquitin-immunohistochemical investigation of atypical Pick’s disease without Pick bodies. J Neurol Sci 159:194–201. doi:10.1016/S0022-510X(98)00168-3 PubMedCrossRefGoogle Scholar
  13. 13.
    Ishizawa T, Mattila P, Davies P, Wang D, Dickson DW (2003) Colocalization of tau and alpha-synuclein epitopes in Lewy bodies. J Neuropathol Exp Neurol 62:389–397PubMedGoogle Scholar
  14. 14.
    Kinoshita A, Tomimoto H, Suenaga T, Akiguchi I, Kimura J (1997) Ubiquitin-related cytoskeletal abnormality in frontotemporal dementia: immunohistochemical and immunoelectron microscope studies. Acta Neuropathol 94:67–72. doi:10.1007/s004010050673 PubMedCrossRefGoogle Scholar
  15. 15.
    Kuzuhara S (2007) TDP–43 accumulation in ALS/parkinsonism-dementia complex (ALS/PDC) of the Kii peninsula of Japan. Neuropathology 27:61 abstrGoogle Scholar
  16. 16.
    Lin WL, Lewis J, Yen SH, Hutton M, Dickson DW (2003) Filamentous tau in oligodendrocytes and astrocytes of transgenic mice expressing the human tau isoform with the P301L mutation. Am J Pathol 162:213–218PubMedGoogle Scholar
  17. 17.
    Nakashima-Yasuda H, Uryu K, Robinson J, Xie SX, Hurtig HI, Duda JE et al (2007) Co-morbidity of TDP-43 proteinopathy in Lewy body related disease. Acta Neuropathol 114:221–229. doi:10.1007/s00401-007-0261-2 PubMedCrossRefGoogle Scholar
  18. 18.
    Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT et al (2006) Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314:130–133. doi:10.1126/science.1134108 PubMedCrossRefGoogle Scholar
  19. 19.
    Okamoto K, Murakami N, Kusaka H, Yoshida M, Hashizume Y, Nakazato Y et al (1992) Ubiquitin-positive intraneuronal inclusions in the extramotor cortices of presenile dementia patients with motor neuron disease. J Neurol 239:426–430. doi:10.1007/BF00856806 PubMedCrossRefGoogle Scholar
  20. 20.
    Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A et al (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science 276:2045–2047. doi:10.1126/science.276.5321.2045 PubMedCrossRefGoogle Scholar
  21. 21.
    Wang I-F, Wu L-S, Chang H-Y, Shen C-K (2008) TDP-43, the signature protein of FTLD-U is a neuronal activity-responsive factor. J Neurochem 105:797–806. doi:10.1111/j.1471-4159.2007.05190.x PubMedCrossRefGoogle Scholar
  22. 22.
    Zhang Y-J, Xu Y-F, Dickey CA, Buratti E, Baralle F, Bailey R et al (2007) Progranulin mediates caspase-dependent cleavage of TAR DNA binding protein-43. J Neurosci 27:10530–10534. doi:10.1523/JNEUROSCI.3421-07.2007 PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  1. 1.Department of NeuroscienceMayo Clinic College of MedicineJacksonvilleUSA

Personalised recommendations